ESR1 and breast carcinoma: Pathway analysis in three independent clinical studies (performed using both Affymetrix microarray- and qPCR-based pathway analysis) showed that in primary ER positive breast cancer patients, the ER pathway activity score predicted response to neoadjuvant treatment with an aromatase inhibitor (Inda et al., 2020).